Gain Therapeutics, Inc. SEC Filings

Key take-away: On 06/24/2025 Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Claude Nicaise received a stock option covering 15,000 shares of common stock at an exercise price of $1.79 per share, expiring on 06/24/2035.

The option was awarded, not exercised, and therefore does not immediately affect the public float. Vesting occurs in 12 equal monthly tranches starting 07/24/2025, contingent on Mr. Nicaise’s continued service. After the grant, the director directly holds 15,000 derivative securities; no non-derivative holdings or sales were reported.

This represents routine equity compensation aimed at further aligning board incentives with shareholder interests. No cash changed hands and no other material transactions were disclosed in this filing.

Key take-away: Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Jeffrey Scott Riley received a grant of 15,000 stock options on 06/24/2025.

The option has an exercise price of $1.79 per share and expires on 06/24/2035. The transaction is coded “A” (acquisition) and represents the only derivative security currently reported for the director; no common shares were bought or sold.

Vesting schedule: the award vests in 12 equal monthly installments beginning 07/24/2025, provided Mr. Riley continues his service. Following the grant he beneficially owns 15,000 options, classified as direct ownership. No indirect holdings or Rule 10b5-1 trading plan were indicated.

Investor relevance: This filing reflects standard director compensation and does not involve open-market buying or selling. While the grant modestly increases potential future dilution, its size is immaterial relative to GANX’s total shares outstanding. The filing may signal management’s effort to align director incentives with shareholder value but is unlikely to move the stock on its own.

Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing a routine equity award to director Eric I. Richman. On 06/24/2025 the director received 15,000 stock options with an exercise price of $1.79 per share.

The options vest in 12 equal monthly installments beginning 07/24/2025, contingent on continued board service, and expire on 06/24/2035. Following the grant, Richman beneficially owns 15,000 derivative securities, all held directly. No shares of common stock were bought or sold, and no other transactions were reported.

Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Hans Peter Hasler received 15,000 stock options on 06/24/2025. The options carry a $1.79 exercise price, expire on 06/24/2035, and will vest in 12 equal monthly tranches beginning 07/24/2025, contingent on continued board service. No common shares were bought or sold; the filing solely reflects an equity-incentive grant. After the transaction, Hasler beneficially owns 15,000 derivative securities, all held directly. The grant is routine board compensation and does not signal any change in the company’s operating outlook, capital structure, or insider sentiment.

Gain Therapeutics, Inc. (GANX) – Director equity award filing.

On 06/24/2025 director Dr. Dov A. Goldstein filed a Form 4 disclosing the receipt of a stock option for 15,000 common shares at an exercise price of $1.79 per share. The option vests in 12 equal monthly installments beginning 07/24/2025, contingent on the director’s continued service, and carries a 10-year term expiring 06/24/2035.

No common shares were bought or sold; the only reportable event is the option grant. After the transaction, Dr. Goldstein holds 15,000 derivative securities, all in direct ownership form. The filing does not reference any Rule 10b5-1 plan, open-market purchase, or disposition, and there is no indication of additional indirect holdings.

The award appears to be routine director compensation designed to align incentives rather than a signal of a major strategic development. The relatively small size versus GANX’s share count limits any dilution or immediate valuation impact, but it modestly increases insider exposure to the company’s equity performance.

Gain Therapeutics, Inc. (GANX) – Form 4 insider filing

Director Gwen A. Melincoff reported the grant of a derivative security in the form of a stock option for 15,000 common shares on 24 June 2025. The option carries an exercise price of $1.79 per share and will expire on 24 June 2035.

Vesting schedule: the option vests in 12 equal monthly instalments beginning 24 July 2025, contingent on the director’s continued service. No sales, exercises, or other dispositions were reported, and the filing shows direct ownership ("D") of the entire option position.

The filing does not list any non-derivative share transactions, cash compensation, or other equity awards. Because Form 4 must be filed within two business days of a reportable event, this document confirms the timely disclosure of the grant.

For investors, the grant represents routine director compensation and involves a limited potential dilution relative to Gain Therapeutics’ outstanding share count. No immediate cash outlay by the insider was required, and there is no indication of open-market buying or selling.

Gain Therapeutics (GANX) held its Annual Meeting on June 24, 2025, where stockholders approved several key proposals. Most significantly, shareholders approved doubling the company's authorized common stock from 50 million to 100 million shares, with 16.3M votes in favor versus 2.2M against.

The meeting also resulted in the following outcomes:

• All eight director nominees were successfully elected to one-year terms, with Gene Mack, Dov Goldstein, and Gwen Melincoff receiving the highest approval rates
• Ernst & Young AG's appointment as independent auditor was ratified with strong support (18M votes in favor)
• A contingency measure for meeting adjournment was approved with 17.9M supporting votes

The company, an emerging growth company listed on Nasdaq, filed the Certificate of Amendment with Delaware's Secretary of State to formally implement the authorized share increase. This expansion of authorized shares could provide additional flexibility for future capital raising or strategic transactions.